Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
Part of paid clinical trials in Denver, Colorado.
- Sponsor
- US Oncology Research
- Study ID
- NCT00250861
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
- Aldesleukin — DRUG
Study Details
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration (FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by itself to treat NHL.
Key Dates
- Start date
- Oct 31, 2005
- Status verified
- Apr 2008
- Primary completion
- Aug 31, 2007
- Completion
- Aug 31, 2007
Study Design
- Enrollment
- 110 participants
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Locations (21)
Find similar trials in Denver, CO
By research site
Rocky Mountain Cancer Center-Midtown· Denver, COHematology Oncology Associates of IL· Chicago, ILCancer Care & Hematology Specialists of Chicagoland· Niles, ILMinnesota Oncology Hematology, PA· Minneapolis, MNKansas City Cancer Centers-Central· Kansas City, MOGreater Dayton Cancer Center· Kettering, OH
Related Studies
- Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALEPHASE1 · Recruiting · Baylor College of Medicine · Houston, Texas
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruiting · Stanford University · Duarte, California
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)PHASE1/PHASE2 · Recruiting · Estrella Biopharma, Inc. · Sacramento, California
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaPHASE1 · Recruiting · AbbVie · Huntersville, North Carolina